Get started

PHARMA

#PHA/USDT#PHA The price is moving in a bearish channel pattern on the 4-hour frame, and it adheres to it well, and it is expected to break to the upside The price rebounded well from the lower border of the channel at the green support level 0.1650, which is a strong level. We have a tendency to stabilize above the Moving Average 100 We have oversold resistance on the RSI indicator to support the rise, with a downtrend about to break higher Entry price is 0.1900 The first target is 0.2330 The second target is 0.2600 The third goal is 0.2884
Long
by CryptoAnalystSignal
PILL 3x Leverage Medical/ Pharma ETF for swing LONGAMEX:PILL On the 4H Chart, current market price is sitting on the support of order blocks and the EMA200, while in an uptend from a double bottom in the sprint. It is moving into the high volume area of the voluxme profile. For the swing trade, the stop loss is $0.10 below the EMA200 while the targets are marked based on a combination of the horizontal resistances of prior swing pivots along with sell order blocks and the structure of the volume profile. Accordingly, this trade risks $0.60 for about $ 4 to $ 5 of upside making for an excellent swing setup especially since healthcare, medical and pharmacueticals are known to be recession resilient and ETFs are inherently diversified making leveraging a risk probably worth taking.
AMEX:PILLLong
by AwesomeAvani
In 3 Months every month end 10 % for 90 Days Say What? Have lookAchyut Healthcare Ltd is a pharmaceutical trading company that was established in 1996 and is based in Ahmedabad, Gujarat. The company trades in pharmaceutical products, medical devices, and APIs. It manufactures tablets, capsules, oral liquids, and injectables, and also customizes products for domestic and international markets. looking for 59 price in upcoming days of 90 in ACHYUT FROM TODAY 9 APRIL 24 CMP 44.70 MAIL US FOR MORE
BSE:ACHYUTLong
by EasyLife_Advisor
Gilead Sciences (GILD): Chances in Pharma Beyond TechGilead Sciences (GILD): NASDAQ:GILD We're aiming to diversify our portfolio beyond just tech stocks and the tech sector. We're now focusing on companies in the pharmaceutical industry, such as Gilead Sciences. Analyzing the weekly chart, we observed the largest surge since 2010 for Wave (3). We believe we've also completed Wave (4) at $56.56. The peak was at $123.27, marking our all-time high. This figure is our target for the minimum achievement for Wave 3. It's crucial, and significantly, we anticipate a high selling pressure at this level. Zooming in, we presume we are in Wave 2, expected to conclude between 61.8% and 78.6% retracement. This positions us with a relatively favorable risk-to-reward ratio on the daily chart. Should we drop below this 78.6% retracement level, we could fall back to $56. If that happens, we'll face a problem, potentially falling further for Wave (4) to a maximum of $30. If this decline doesn't materialize, we'll continue to anticipate an upward movement.
NASDAQ:GILDLong
by freeguy_by_wmc
1
$OGI - 9-years forecast for the company sharesSo funny and amazing, when you had prepared a long-term vision for a company just 2 days ago, but did not published for a while, and purely by chance get notices, that this company has grown today for almost 250% in some hours. So, nevertheless, this only confirmed, that signals, which were seen are correct and I still can publish my forecast for almost 10 years ahead. I see a huge divergence on 1w timerange and NASDAQ:OGI was able to accumulate a huge potential for the future ascending motion. Being on the bottom and turning around, it has an energy to show perfect plus even from the current values. Of cause, after so enormous jump today, we will observe some kind of correction, but for investors this fact can't be a problem. Good company, fields of the future with a possible nice results. I believe, it will keep on moving to the top. Goal number 1 for 1 year is 4.5 Does not constitute a recommendation. #investing #stocks #idea #forecast #furoreggs Please, subscribe and challenge my point of view )
NASDAQ:OGILong
by furoreggs
2
ILMN Bullish ComebackOn the 12 month timeframe, or yearly supercycle, ILMN seems to be consolidating enough these first 3 months into 2024 to ultimately flip to the upside with maximum bull force. The company has a solid catalyst with AI facilitating the end goal of a super biopharma product that perhaps all humanity may have to rely on: a panacea. This panacea may come in the form of a machine that prompts the users exactly what symptoms they have, and produce a medicine that cures said symptoms. Something very well regulated and sophisticated enough to fuel the bull run of the decade for ILMN. A merger should be the cherry on top, and maybe the BNGO merger prophecy comes to fruition, but this only time will tell.
NASDAQ:ILMNLong
by JuanLagos94
ALKEM Near All time high ALKEM is Near all time high Alkem is in a Rising channel and Resistance is working from last 8 years Stock is facing resistance around 5500 for the further upside Stock need to cross 5500 If stock tanks then we might see level of 3100-3200 3100-3200 is strongest support and one should not miss opportunity to BUY around these levels. Thank You !! Disclaimer : We are not SEBI registered analyst. Do your own research before taking any investment decision.
NSE:ALKEMShort
by FiveCircles
Pioneering Cancer Treatment with QINLOCK and VimseltinibIntroduction Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) is at the forefront of developing innovative cancer treatments, with a keen focus on leveraging their proprietary switch-control kinase inhibitor platform. The company has made significant strides, particularly with its flagship product, QINLOCK, and the promising pipeline candidate vimseltinib, aiming for a transformative year in 2024. Revenue and Profit Forecasts Deciphera has projected an optimistic financial trajectory for 2023, with preliminary unaudited revenue for the fourth quarter estimated at approximately $47 million and full-year revenue expected to be around $162 million. This growth is largely attributed to the robust sales of QINLOCK, which alone contributed roughly $46 million in net product revenue in Q4 2023. The company's financial health is further underscored by its substantial cash reserves, amounting to approximately $352 million as of the end of 2023, ensuring operational and capital expenditure funding well into the second half of 2026​​​​. Growth Drivers The continued expansion and commercial success of QINLOCK in treating gastrointestinal stromal tumor (GIST) patients, along with the strategic rollout of vimseltinib for the treatment of Tenosynovial Giant Cell Tumor (TGCT) and potential applications in chronic graft versus host disease (cGVHD), underscore Deciphera's growth trajectory. The company's strategic partnerships, such as the distribution agreement with GENESIS Pharma for QINLOCK in Central and Eastern Europe, are pivotal to its international market expansion​​​​. Recent Financial Performance Deciphera's earnings in Q4 2023 beat analyst expectations, reporting an EPS of -$0.54 against the anticipated -$0.58. This performance reflects a 32.9% increase in quarterly revenue year-over-year, indicating strong commercial execution and market acceptance of its products. Analysts remain optimistic about the company's future earnings, projecting gradual EPS improvement through 2025​​. Technical and Market Outlook Deciphera's technical indicators and market sentiment appear positive, buoyed by recent financial results and the potential for its pipeline candidates. The company's strategic focus on developing first-in-class and best-in-class treatments for cancer positions it well within the biopharmaceutical sector for sustained growth and innovation​​​​. Conclusion Deciphera Pharmaceuticals is poised for significant growth in 2024 and beyond, driven by its innovative product portfolio, strategic market expansions, and strong financial position. With QINLOCK's continued success and the anticipated commercial launch of vimseltinib, Deciphera is on the cusp of evolving into a self-sustaining, multi-product company. As it advances its mission to improve the lives of people with cancer, the biopharmaceutical firm remains a compelling entity within the oncology space, promising exciting developments for investors and patients alike. ---------------- NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
DLong
by olimchik
Axsome Therapeutics - $AXSM - The Long Term PlayAxsome Therapeutics - NASDAQ:AXSM ▫️ Entered a position in Oct 2022 on the bounce off the 200 week SMA (averaging $50.77c per share) ▫️ That position is presently in 73% profit ▫️ I have no intention of selling at present as we have a strong underside support from the 200 week MA, the 200 day MA and high volume trading zone from $70-78. ▫️ This a longer term play however I think an entry from within the above price zone ($70-78) or having a stop placed under it, if you can weather such a decline would be worthy of a long term position. Earnings are on the 20th Feb 2024 👀 however the chart is my lead. I look at earnings for long term DCA opportunities When I initially entered this position I had a 3-4 year time frame in mind. We are 15 months in and sitting pretty at 73% Profit. Patience pays dividends.
NASDAQ:AXSMLong
by PukaCharts
Eli Lilly Breaks New Ground With Weight Loss Drug Offering Eli Lilly - NYSE:LLY Earnings Rep: $2.49 ✅ Exp: $2.29 - 8.45% HIGHER Revenue Rep: $9.35b ✅ Exp: $8.94b - 4.55% HIGHER Company Summary Eli Lilly is the worlds 9th largest company by market cap at $670b and they have reported positive earnings and revenue both coming in higher than expected for Q4 2023. The pharmaceutical giant booked fourth-quarter revenue of $9.35 billion, up 28% from the same period a year ago. A massive result that is reflected in the chart and pre-market surge in price per a share from €706 - €740 👀 Eli develop and manufacture a series of medications with their top drugs being for diabetes and cancer. The diabetes drug Trulicity generated more than $7.4 billion in revenue for Eli Lilly in 2022 accounting for more than one-quarter of the company's top line, which totaled $28.5 billion. Meanwhile for 2023, Trulicity, reported $1.67 billion in revenue. That’s down 14% from the same period a year go however remains a large revenue generator. Mounjaro booked $2.21 billion in sales for the fourth quarter and remains one of the companies core diabetes products. The Q4 2023 results are the first to include sales of Eli Lilly’s new weight loss drug Zepbound, which won FDA approval in early Nov 2023. Zepbound resulted in $175.8 million in sales for Q4. Analysts are expecting a minimum of $1 billion in sales for the 2024 period and some are claiming that Zepbound could become the biggest drug of all time. Do you feel that AI style narrative euphoria building here? Now more importantly, Lets check out this chart The Chart The chart here really caught my attention, its one of thee strongest long term charts I have come across and it keeps making higher double bottoms off higher moving averages. The OBV is increasing still and the support line might be a good line to watch got an entry bounce or a break down (exit) - a trigger level. PUKA
NYSE:LLYLong
by PukaCharts
NATCO PHARMA LTD - READY TO BREAKOUTEntry Possible above 950 level SL - 720 Short term Target - 1190 Long term Target - 1500 Disclaimer - All information on this page is for educational purposes only, we are not SEBI Registered, Please consult a SEBI registered financial advisor for your financial matters before investing And taking any decision. We are not responsible for any profit/loss you made. Request your support and engagement by liking and commenting & follow to provide encouragement HAPPY TRADING 👍
NSE:NATCOPHARMLong
by Jagadheesh_JP
Cup and Handle kind of Breakout on cards for Pharma Index. Technically Pharma index is on the verge of giving a cup and handle like breakout in addition to news of new COVID variant making waves. The Pharma index also looking very buoyant. If this particular index can give a closing above 16515 there can be an upsurge 16734 or even 17177 levels taking the index constituents higher along with it. Major companies in pharma index are Abbott, Cipla, Glaxo, Sanofi, Pfizer, Dr Reddy's, Lupin, Torrent Pharam, Ipca Labs, Sun Pharma, Aurobind Pharma, Natco Pharma, Granules India, Gland Pharma, Alkem, Biocon, Glenmark, Zydus Lifescience, Divi's lab, Laurus lab. Some companies good companies of Mid and Small cap pharma can also yield positive momentum. Post identification of a strong index what you can do is try to look at the charts of each constituent of the index individually and select the stocks with best EPS, PE ratio, Good Cash flow from operations, Revenue and Net Profit growing year on year and quarter on quarter. Remember that now all the stocks in an index will move equally some will move faster, some will move at the same pace, some will move slowly and some will not move at all or move negatively. You have to be smart in selection of your stocks from the particular index and you will surely be able to beat the market and Ace the art of investing. There are many Pharma related Mutual funds that can also be looked at. Disclaimer: Investment in stocks and mutual funds is subject to market risks, please consult your investment advisor before taking financial decisions. The data provided above is for the purpose of analysis and is purely educational in nature. The names of the stocks given in the above article and chart of IT Index is only for analysis. Purpose of this article is educational. Please do not consider this as a recommendation of any sorts.
NSE:CNXPHARMALong
by Happy_Candles_Investment
Granules India Limited: A Promising Stock with Strong Earnings GRANULES INDIA SHARE BUY NOW ON 288 SELL AFTER ATLEAST PROFIT OF 28 % ITS A INVESTMENT RECOS FOR INTRA RECOS wsip me 8459 22 0202 Granules India Limited is a pharmaceutical company that offers a wide range of products and services. The company has a robust business model, with a strong focus on research and development, which allows it to stay ahead of the competition. Additionally, the company's products are in high demand, as the pharmaceutical industry is growing rapidly. The company has also been consistently reporting strong earnings, which is a positive indicator of its financial health. Overall, Granules India Limited is a promising stock with strong earnings potential and a positive outlook in the pharmaceutical industry, making it a smart investment opportunity.
NSE:GRANULESLong
by EasyLife_Advisor
1